Pfizer, the world’s largest pharmaceutical company, has decided to invest 90.5 million euros ($95.24 million) in Valneva, a French Vaccine company, as the businesses reported further advancements in their Lyme disease collaboration. Pfizer will purchase a 9.49 euro per share interest in Valneva, which is also developing the COVID-19 vaccine, through a restricted capital increase. […]

The post Pfizer To Buy 8.1% Equity In Valneva, A French Vaccine Firm first appeared on World Pharma Today.